Percutaneous Microwave Ablation of Renal Cell Carcinoma (RCC)
Renal cell carcinoma (RCC) accounts for 3% of malignancies in adults and 80-90% of malignant renal tumors. It is the seventh most common cancer in men and the ninth most common cancer in women. Partial or radical nephrectomies have been the leading course of treatment. However, in the recent years, there has been a surge in the usage of various minimally invasive ablation techniques to treat small (equal to or less than 4 cm) soft tissue tumors in order to preserve renal function. This is a registry of patients diagnosed with renal masses who are treated by percutaneous microwave ablation. Patients treated with percutaneous microwave ablation will be consented prior to their procedure to allow us to collect their data before they are treated, during their treatment and during their follow up.
This study is currently enrolling.
Interested in participating?
Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.